<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680833</url>
  </required_header>
  <id_info>
    <org_study_id>RegionSkaneKKLund2</org_study_id>
    <nct_id>NCT03680833</nct_id>
  </id_info>
  <brief_title>Sentinel Node Detection in Cervical Cancer</brief_title>
  <acronym>SLNcxca</acronym>
  <official_title>Sentinel Node Detection in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of sensitivity of Sentinel lymph nodes for detecting nodal metastases in cervical
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive women with stage 1a2-2a1 cervical cancer scheduled for surgery will be approached
      for eligibility by defined criteria.

      Sentinel nodes will be detected by a combined use of Indocyanine green and Tc99 radiocolloid
      ( first 75 patients) and for the continuation with either the combined use or the best
      performing of those tracers.

      Technical success rates, adverse events (related study intervention and overall) sensitivity
      and negative predictive values will be estimated.

      An interim analyse will be performed after 34 node positive patients based on the Fleming two
      stage analyse. The null hypothesis of sensitivity of 85% will be tested against an estimated
      sensitivity of 95%. At this stage the study may be closed for futility, closed as hull
      hypothesis is rejected or continued to reach another 28 node positive patients.

      As a full pelvic lymphadenectomy will be performed after detection of sentinel nodes patient
      will act ast their own controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective cohort study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sentinel node detection in cervical cancer; Sensitivity and negative predictive values for identifying pelvic nodal disease, See detailed study protocol</measure>
    <time_frame>4-5 years</time_frame>
    <description>Detection of Sentinel nodes followed by full pelvic lymphadenectomy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Sentinel Lymph Node Biopsy</condition>
  <arm_group>
    <arm_group_label>prospective cohort study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.
The intervention is the detection and removal of sentinel lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node detection in cervical cancer</intervention_name>
    <description>The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes</description>
    <arm_group_label>prospective cohort study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of age 18 years and older at the time of informed consent.

          -  Women with a pathologically proven cervical carcinoma of any histologic subtype,
             clinically stage 1a2- 2a1 planned for primary surgery

          -  Absence of any exclusion criteria

        Exclusion Criteria:

          -  Non consenting patients

          -  Ongoing pregnancy

          -  Inability to understand written and/or oral study information

          -  Who performance status III or more

          -  Previous lower limb lymphedema

          -  Surgical contraindication to a laparoscopic approach or lymphadenectomy at surgeons
             discretion.

          -  Anesthesiologic contraindication to a laparoscopic approach at the anesthetist's
             discretion

          -  Locally advanced disease or intraabdominal/distant metastases at preoperative CT, MRI
             or ultrasonography

          -  Radiologically suspect pelvic nodal metastatic disease according to the RECIST
             criteria (&gt;= 1 node with &gt;=16 mm short axis diameter)

          -  Allergy to Iodine

          -  Patients with a known liver disease

          -  Patients with a significant bleeding disorder or mandatory antithrombotic treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Persson, ass professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Persson, ass professor</last_name>
    <phone>+46733522080</phone>
    <email>jan.persson@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linnea Ekdahl, MD</last_name>
    <phone>0739292631</phone>
    <email>linnea.ekdahl@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Persson, ass professor</last_name>
      <phone>+46733522080</phone>
      <email>jan.persson@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Linnea Ekdahl, MD</last_name>
      <phone>+46739292631</phone>
      <email>linnea.ekdahl@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03680833/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

